针对上述提问，万达信息回应称："感谢您对万达信息的关注。万达信息垂类大模型聚焦医疗健康领 域，可运用于辅助医疗和公共卫生等多个场景。精准健康认知计算系统——灵素融入OCR和大模型能 力，可以提供多项检后健康管理智能服务，包括体检报告的识别检测、报告解读及健康干预。白泽晓医 疗大模型结合医疗公卫、健康管理等服务需求，在实时知识问答、事件与病历内容理解、多模态病历生 成、辅助诊疗决策及专病健康管理等各类应用场景创新赋能，有面向B端和C端的应用，目前已在多家 医院试点使用。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向万达信息提问："近期阿里旗下的蚂蚁阿福热度很高，成为下载榜前列，公司医 疗大模型与蚂蚁阿福水平相比如何？是否通过中国人寿嵌入其app或者单独也推出一个面向大众的 app？" 来源：市场资讯 ...

（记者 胡玲） 每经AI快讯，万达信息（300168.SZ）12月23日在投资者互动平台表示，万达信息垂类大模型聚焦医疗 健康领域，可运用于辅助医疗和公共卫生等多个场景。精准健康认知计算系统——灵素融入OCR和大 模型能力，可以提供多项检后健康管理智能服务，包括体检报告的识别检测、报告解读及健康干预。白 泽晓医疗大模型结合医疗公卫、健康管理等服务需求，在实时知识问答、事件与病历内容理解、多模态 病历生成、辅助诊疗决策及专病健康管理等各类应用场景创新赋能，有面向B端和C端的应用，目前已 在多家医院试点使用。 ...

Group 1 - The core viewpoint of the news is that Wanda Information's stock has experienced a decline of 19.65% this year, with a recent drop of 2.15% on December 23, trading at 6.38 yuan per share [1] - As of December 10, the number of shareholders for Wanda Information is 56,400, a decrease of 2.71% from the previous period, while the average circulating shares per person increased by 2.79% to 25,538 shares [2] - For the period from January to September 2025, Wanda Information reported a revenue of 1.329 billion yuan, reflecting a year-on-year growth of 0.57%, while the net profit attributable to shareholders was -408 million yuan, showing a year-on-year increase of 27.07% [2] Group 2 - Wanda Information has cumulatively distributed 292 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3] - As of September 30, 2025, the top ten circulating shareholders of Wanda Information include Hong Kong Central Clearing Limited, which holds 9.7795 million shares, a decrease of 2.6443 million shares from the previous period [3] - The company's main business involves software development and services in the urban informationization sector, with revenue composition being 47.86% from software development, 32.37% from operation and maintenance services, and 19.74% from integration services [1]

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2025-12-22 | 300168 | 万达信息 | 6.49 | 100.00 | | 649.00 中信建投证券股份 有限公司北京东城 分公司 | 机构专用 | 12月22日，万达信息大宗交易成交100万股，成交额649万元，占当日总成交额的5.93%，成交价6.49 元，较市场收盘价6.52元折价0.46%。 ...

Group 1 - The core point of the article highlights the trading activity of Wanda Information, which experienced a decline of 1.36% on December 22, closing at 6.52 yuan, with a significant block trade of 1 million shares amounting to 6.49 million yuan [1] - The first transaction was executed at a price of 6.49 yuan for 1 million shares, resulting in a transaction amount of 6.49 million yuan, with a premium rate of -0.46%. The buyer was CITIC Jianzhong Securities Co., Ltd., Beijing Dongcheng Branch, and the seller was an institutional entity [1] - Over the past three months, Wanda Information has recorded a total of 24 block trades, with a cumulative transaction amount of 172 million yuan. In the last five trading days, the stock has increased by 3.00%, while the net outflow of main funds totaled 9.97 million yuan [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事、高级副总裁辞职情况 万达信息股份有限公司（以下简称"公司"）董事会于 2025 年 12 月 19 日收 到公司董事、高级副总裁吴洪伟先生的书面辞职报告。吴洪伟先生因个人原因， 申请辞去公司第八届董事会董事、高级副总裁职务，辞职后不再担任公司任何职 务。吴洪伟先生向董事会确认其与董事会并无意见分歧，亦无其他因辞职而需知 会股东的事宜。 吴洪伟先生作为公司第八届董事会董事的原定任期为 2023 年 7 月 26 日至 2026 年 7 月 25 日。截至本公告日，吴洪伟先生未直接或间接持有公司股份。吴 洪伟先生的辞任未导致董事会成员低于法定最低人数，不会对公司日常生产经营 和管理产生不利影响，吴洪伟先生的辞职报告自送达董事会之日起生效，将按照 规定做好工作交接。 证券代码：300168 证券简称：万达信息 公告编号：2025-072 万达信息股份有限公司 关于董事、高级副总裁辞职暨选举职工代表董事的公告 公司及董事会对吴洪伟先生在担任公司董事、高级副总裁职务期间的工作表 示衷心感谢。 二、选举职工代表董事 ...

Group 1 - A total of 78 stocks in the A-share market experienced block trading today, with a total transaction value of 3.755 billion yuan [1] - The top three stocks by transaction value were Minsheng Bank (2.149 billion yuan), WuXi AppTec (430 million yuan), and Luxin Technology (119 million yuan) [1] - Among the stocks, 8 were traded at par, 3 at a premium, and 67 at a discount; the highest premium rates were for AVIC Optoelectronics (8.04%), Zhongke Shuguang (7.92%), and Haowei Group (2.07%) [1] Group 2 - The top buying amounts from institutional special seats were led by WuXi AppTec (251 million yuan) and Minsheng Bank (108 million yuan) [2] - The top selling amounts from institutional special seats included Jintian Titanium Industry (18.74 million yuan) and Huilong New Materials (9.97 million yuan) [2]

Core Viewpoint - The company is focusing on the development of industry AI platforms and intelligent applications, particularly in the fields of public health, medical services, and convenience services, while promoting the AI upgrade of its core product, the national health information platform [1] Group 1: AI Development and Applications - The company is advancing its "AI + public health," "AI + medical services," "AI + convenience services," and "AI + industry regulation" initiatives [1] - Significant progress has been made in the medical AI sector, with the development of an intelligent medical platform that empowers the core medical circle in the Yangtze River Delta [1] - The company has established a national intelligent engine base to support high-frequency application scenarios such as "Smart Handling," "One-Stop Service," and "Enjoy Without Application" [1] Group 2: Innovative Service Models - The company has innovated service models like "Ask While Handling" and "Ask While Inspecting," embedding intelligent services throughout the administrative process [1] - These innovations effectively address challenges in the governance AI model, such as the scarcity of deep scenarios, difficulties in transformation, and high security requirements [1] Group 3: AI Product Portfolio - The company has developed a range of AI products, including Shuzhitong, Shuyitong, a medical health knowledge platform, a large model support platform, Baize Xiao medical large model platform, intelligent care boxes for elderly care, pathology AI model services, and Ling Su health report interpretation [1]

Core Insights - The company focuses on the development of industry AI platforms and intelligent agents, promoting applications in public health, medical services, convenience services, and industry regulation [1] - The company has made significant advancements in the medical AI sector, successfully empowering the core medical circle in the Yangtze River Delta with its self-developed intelligent medical platform [1] Business Development - The company is accelerating the implementation of digital health intelligent applications and promoting innovative development of "AI+" applications in the public health sector [1] - The company has established a national intelligent engine base to support high-frequency application scenarios such as "Smart Handling," "One-Stop Service," and "Enjoy Without Application" [1] Product Innovation - The company has developed various AI products, including Shuzhitong, Shuyitong, a medical health knowledge platform, a large model support platform, Baize Xiao medical large model platform, intelligent care boxes for elderly monitoring, pathology AI model services, and Ling Su health report interpretation [1] Financial Performance - For the period from January to September 2025, the company achieved a revenue of 1.329 billion yuan, representing a year-on-year growth of 0.57% [1] - The company reported a net loss of 408 million yuan, which is a year-on-year reduction in loss by 27.07% [1]

Core Viewpoint - The company is focused on optimizing its operational strategies to enhance profitability and improve its market value, emphasizing the importance of effective communication with investors to build confidence in long-term stock holdings [2]. Group 1: Operational Strategies - The company is implementing five key measures to enhance its core competitiveness and profitability, aiming for sustainable development [2]. - There is a focus on improving market development capabilities, enhancing order quality, and increasing revenue conversion [2]. - The company aims to strengthen its sales team, improve sales capabilities, and optimize pricing structures to increase order amounts and quality [2]. Group 2: Innovation and R&D - The company is committed to strengthening its research and development efforts, fostering new productive forces, and integrating technological innovation with core business operations [2]. - There is an emphasis on upgrading products and solutions based on market demands and customer pain points, as well as enhancing the technical integration capabilities of business operations [2]. - The company plans to optimize its system architecture and conduct regular evaluations to improve its core competitiveness [2]. Group 3: Cost Management and Efficiency - The company is focusing on budget management, dynamic monitoring of budget execution, and optimizing resource allocation to control costs [2]. - There is a strategy to improve subsidiary management and close underperforming subsidiaries while promoting accounts receivable recovery through various measures [2]. - The company aims to enhance compliance systems and cultivate a compliance awareness among all employees to strengthen risk prevention and management capabilities [2]. Group 4: Collaboration with Major Shareholders - The company seeks to deepen collaboration with major shareholders, particularly in areas such as insurance technology, health, and elderly care, to consolidate existing synergies [2]. - There is an intention to explore new business collaborations and expand development opportunities in different regions with major shareholders [2].